Literature DB >> 11177751

Multiple daily fractionation radiotherapy schedules in lung cancer.

C A Schulz1, P M Harari, M P Mehta.   

Abstract

Lung cancer is the number one worldwide cancer killer, and in spite of therapeutic advances, the overall impact on survival has remained very modest. For both small and non-small-cell lung cancer, treatment trends have shifted toward combined-modality approaches, chemotherapy for the control of systemic micrometastases, and radiotherapy for intrathoracic control. However, on both counts, rates of failure remain unacceptably high, and several novel strategies are currently being explored. The use of altered fractionation, including multiple daily fractions, reflects one approach for modifying radiotherapy. The two most common approaches are hyperfractionation and acceleration, the former designed to reduce late normal tissue toxicities and the latter to counteract accelerated tumor repopulation. Recent randomized trials suggest that such approaches may result not only in lowered rates of intrathoracic failure but also in improved survival.

Entities:  

Mesh:

Year:  2001        PMID: 11177751     DOI: 10.1007/s11912-001-0019-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  20 in total

1.  Non-small cell lung tumors repopulate rapidly during radiation therapy.

Authors:  J F Fowler; R Chappell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

2.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors:  J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

3.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.

Authors:  M Saunders; S Dische; A Barrett; A Harvey; G Griffiths; M Palmar
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

4.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

Authors:  W T Sause; C Scott; S Taylor; D Johnson; R Livingston; R Komaki; B Emami; W J Curran; R W Byhardt; A T Turrisi
Journal:  J Natl Cancer Inst       Date:  1995-02-01       Impact factor: 13.506

5.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

6.  Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.

Authors:  B Jeremic; Y Shibamoto; L Acimovic; S Milisavljevic
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.

Authors:  R W Byhardt; T F Pajak; B Emami; A Herskovic; R S Doggett; L A Olsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-06-15       Impact factor: 7.038

8.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.

Authors:  J D Cox; T F Pajak; S Asbell; A H Russell; J Pederson; R W Byhardt; B Emami; M Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-10-20       Impact factor: 7.038

9.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.

Authors:  B Jeremic; Y Shibamoto; L Acimovic; L Djuric
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.

Authors:  M P Mehta; S P Tannehill; S Adak; L Martin; D G Petereit; H Wagner; J F Fowler; D Johnson
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

View more
  3 in total

1.  Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.

Authors:  Nitin Ohri; Maria Werner-Wasik; Inga S Grills; José Belderbos; Andrew Hope; Di Yan; Larry L Kestin; Matthias Guckenberger; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-01       Impact factor: 7.038

2.  Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite.

Authors:  J Uzan; A E Nahum
Journal:  Br J Radiol       Date:  2012-03-28       Impact factor: 3.039

3.  Dose-dependent and independent temporal patterns of gene responses to ionizing radiation in normal and tumor cells and tumor xenografts.

Authors:  N N Khodarev; J O Park; J Yu; N Gupta; E Nodzenski; B Roizman; R R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.